What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Andrea Palicelli [verfasserIn] Martina Bonacini [verfasserIn] Stefania Croci [verfasserIn] Cristina Magi-Galluzzi [verfasserIn] Sofia Cañete-Portillo [verfasserIn] Alcides Chaux [verfasserIn] Alessandra Bisagni [verfasserIn] Eleonora Zanetti [verfasserIn] Dario De Biase [verfasserIn] Beatrice Melli [verfasserIn] Francesca Sanguedolce [verfasserIn] Magda Zanelli [verfasserIn] Maria Paola Bonasoni [verfasserIn] Loredana De Marco [verfasserIn] Alessandra Soriano [verfasserIn] Stefano Ascani [verfasserIn] Maurizio Zizzo [verfasserIn] Carolina Castro Ruiz [verfasserIn] Antonio De Leo [verfasserIn] Guido Giordano [verfasserIn] Matteo Landriscina [verfasserIn] Giuseppe Carrieri [verfasserIn] Luigi Cormio [verfasserIn] Daniel M. Berney [verfasserIn] Jatin Gandhi [verfasserIn] Giacomo Santandrea [verfasserIn] Maria Carolina Gelli [verfasserIn] Alessandro Tafuni [verfasserIn] Moira Ragazzi [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy

Übergeordnetes Werk:	In: Cells - MDPI AG, 2012, 10(2021), 11, p 3165
Übergeordnetes Werk:	volume:10 ; year:2021 ; number:11, p 3165

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cells10113165

Katalog-ID:	DOAJ073495417

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ073495417
003	DE-627
005	20240412132651.0
007	cr uuu---uuuuu
008	230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cells10113165 \|2 doi
035			\|a (DE-627)DOAJ073495417
035			\|a (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QH573-671
100	0		\|a Andrea Palicelli \|e verfasserin \|4 aut
245	1	0	\|a What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
650		4	\|a PD-L1
650		4	\|a prostate
650		4	\|a cancer
650		4	\|a adenocarcinoma
650		4	\|a immunohistochemistry
650		4	\|a target-therapy
653		0	\|a Cytology
700	0		\|a Martina Bonacini \|e verfasserin \|4 aut
700	0		\|a Stefania Croci \|e verfasserin \|4 aut
700	0		\|a Cristina Magi-Galluzzi \|e verfasserin \|4 aut
700	0		\|a Sofia Cañete-Portillo \|e verfasserin \|4 aut
700	0		\|a Alcides Chaux \|e verfasserin \|4 aut
700	0		\|a Alessandra Bisagni \|e verfasserin \|4 aut
700	0		\|a Eleonora Zanetti \|e verfasserin \|4 aut
700	0		\|a Dario De Biase \|e verfasserin \|4 aut
700	0		\|a Beatrice Melli \|e verfasserin \|4 aut
700	0		\|a Francesca Sanguedolce \|e verfasserin \|4 aut
700	0		\|a Magda Zanelli \|e verfasserin \|4 aut
700	0		\|a Maria Paola Bonasoni \|e verfasserin \|4 aut
700	0		\|a Loredana De Marco \|e verfasserin \|4 aut
700	0		\|a Alessandra Soriano \|e verfasserin \|4 aut
700	0		\|a Stefano Ascani \|e verfasserin \|4 aut
700	0		\|a Maurizio Zizzo \|e verfasserin \|4 aut
700	0		\|a Carolina Castro Ruiz \|e verfasserin \|4 aut
700	0		\|a Antonio De Leo \|e verfasserin \|4 aut
700	0		\|a Guido Giordano \|e verfasserin \|4 aut
700	0		\|a Matteo Landriscina \|e verfasserin \|4 aut
700	0		\|a Giuseppe Carrieri \|e verfasserin \|4 aut
700	0		\|a Luigi Cormio \|e verfasserin \|4 aut
700	0		\|a Daniel M. Berney \|e verfasserin \|4 aut
700	0		\|a Jatin Gandhi \|e verfasserin \|4 aut
700	0		\|a Giacomo Santandrea \|e verfasserin \|4 aut
700	0		\|a Maria Carolina Gelli \|e verfasserin \|4 aut
700	0		\|a Alessandro Tafuni \|e verfasserin \|4 aut
700	0		\|a Moira Ragazzi \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cells \|d MDPI AG, 2012 \|g 10(2021), 11, p 3165 \|w (DE-627)718622081 \|w (DE-600)2661518-6 \|x 20734409 \|7 nnns
773	1	8	\|g volume:10 \|g year:2021 \|g number:11, p 3165
856	4	0	\|u https://doi.org/10.3390/cells10113165 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2073-4409/10/11/3165 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2073-4409 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2021 \|e 11, p 3165

Indexfelder

author_variant	a p ap m b mb s c sc c m g cmg s c p scp a c ac a b ab e z ez d d b ddb b m bm f s fs m z mz m p b mpb l d m ldm a s as s a sa m z mz c c r ccr a d l adl g g gg m l ml g c gc l c lc d m b dmb j g jg g s gs m c g mcg a t at m r mr
matchkey_str	article:20734409:2021----::htoeaeonwbuplepesoipottcneaytmtcieaueeiwat
hierarchy_sort_str	2021
callnumber-subject-code	QH
publishDate	2021
allfields	10.3390/cells10113165 doi (DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f DE-627 ger DE-627 rakwb eng QH573-671 Andrea Palicelli verfasserin aut What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology Martina Bonacini verfasserin aut Stefania Croci verfasserin aut Cristina Magi-Galluzzi verfasserin aut Sofia Cañete-Portillo verfasserin aut Alcides Chaux verfasserin aut Alessandra Bisagni verfasserin aut Eleonora Zanetti verfasserin aut Dario De Biase verfasserin aut Beatrice Melli verfasserin aut Francesca Sanguedolce verfasserin aut Magda Zanelli verfasserin aut Maria Paola Bonasoni verfasserin aut Loredana De Marco verfasserin aut Alessandra Soriano verfasserin aut Stefano Ascani verfasserin aut Maurizio Zizzo verfasserin aut Carolina Castro Ruiz verfasserin aut Antonio De Leo verfasserin aut Guido Giordano verfasserin aut Matteo Landriscina verfasserin aut Giuseppe Carrieri verfasserin aut Luigi Cormio verfasserin aut Daniel M. Berney verfasserin aut Jatin Gandhi verfasserin aut Giacomo Santandrea verfasserin aut Maria Carolina Gelli verfasserin aut Alessandro Tafuni verfasserin aut Moira Ragazzi verfasserin aut In Cells MDPI AG, 2012 10(2021), 11, p 3165 (DE-627)718622081 (DE-600)2661518-6 20734409 nnns volume:10 year:2021 number:11, p 3165 https://doi.org/10.3390/cells10113165 kostenfrei https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f kostenfrei https://www.mdpi.com/2073-4409/10/11/3165 kostenfrei https://doaj.org/toc/2073-4409 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 11, p 3165
spelling	10.3390/cells10113165 doi (DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f DE-627 ger DE-627 rakwb eng QH573-671 Andrea Palicelli verfasserin aut What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology Martina Bonacini verfasserin aut Stefania Croci verfasserin aut Cristina Magi-Galluzzi verfasserin aut Sofia Cañete-Portillo verfasserin aut Alcides Chaux verfasserin aut Alessandra Bisagni verfasserin aut Eleonora Zanetti verfasserin aut Dario De Biase verfasserin aut Beatrice Melli verfasserin aut Francesca Sanguedolce verfasserin aut Magda Zanelli verfasserin aut Maria Paola Bonasoni verfasserin aut Loredana De Marco verfasserin aut Alessandra Soriano verfasserin aut Stefano Ascani verfasserin aut Maurizio Zizzo verfasserin aut Carolina Castro Ruiz verfasserin aut Antonio De Leo verfasserin aut Guido Giordano verfasserin aut Matteo Landriscina verfasserin aut Giuseppe Carrieri verfasserin aut Luigi Cormio verfasserin aut Daniel M. Berney verfasserin aut Jatin Gandhi verfasserin aut Giacomo Santandrea verfasserin aut Maria Carolina Gelli verfasserin aut Alessandro Tafuni verfasserin aut Moira Ragazzi verfasserin aut In Cells MDPI AG, 2012 10(2021), 11, p 3165 (DE-627)718622081 (DE-600)2661518-6 20734409 nnns volume:10 year:2021 number:11, p 3165 https://doi.org/10.3390/cells10113165 kostenfrei https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f kostenfrei https://www.mdpi.com/2073-4409/10/11/3165 kostenfrei https://doaj.org/toc/2073-4409 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 11, p 3165
allfields_unstemmed	10.3390/cells10113165 doi (DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f DE-627 ger DE-627 rakwb eng QH573-671 Andrea Palicelli verfasserin aut What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology Martina Bonacini verfasserin aut Stefania Croci verfasserin aut Cristina Magi-Galluzzi verfasserin aut Sofia Cañete-Portillo verfasserin aut Alcides Chaux verfasserin aut Alessandra Bisagni verfasserin aut Eleonora Zanetti verfasserin aut Dario De Biase verfasserin aut Beatrice Melli verfasserin aut Francesca Sanguedolce verfasserin aut Magda Zanelli verfasserin aut Maria Paola Bonasoni verfasserin aut Loredana De Marco verfasserin aut Alessandra Soriano verfasserin aut Stefano Ascani verfasserin aut Maurizio Zizzo verfasserin aut Carolina Castro Ruiz verfasserin aut Antonio De Leo verfasserin aut Guido Giordano verfasserin aut Matteo Landriscina verfasserin aut Giuseppe Carrieri verfasserin aut Luigi Cormio verfasserin aut Daniel M. Berney verfasserin aut Jatin Gandhi verfasserin aut Giacomo Santandrea verfasserin aut Maria Carolina Gelli verfasserin aut Alessandro Tafuni verfasserin aut Moira Ragazzi verfasserin aut In Cells MDPI AG, 2012 10(2021), 11, p 3165 (DE-627)718622081 (DE-600)2661518-6 20734409 nnns volume:10 year:2021 number:11, p 3165 https://doi.org/10.3390/cells10113165 kostenfrei https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f kostenfrei https://www.mdpi.com/2073-4409/10/11/3165 kostenfrei https://doaj.org/toc/2073-4409 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 11, p 3165
allfieldsGer	10.3390/cells10113165 doi (DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f DE-627 ger DE-627 rakwb eng QH573-671 Andrea Palicelli verfasserin aut What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology Martina Bonacini verfasserin aut Stefania Croci verfasserin aut Cristina Magi-Galluzzi verfasserin aut Sofia Cañete-Portillo verfasserin aut Alcides Chaux verfasserin aut Alessandra Bisagni verfasserin aut Eleonora Zanetti verfasserin aut Dario De Biase verfasserin aut Beatrice Melli verfasserin aut Francesca Sanguedolce verfasserin aut Magda Zanelli verfasserin aut Maria Paola Bonasoni verfasserin aut Loredana De Marco verfasserin aut Alessandra Soriano verfasserin aut Stefano Ascani verfasserin aut Maurizio Zizzo verfasserin aut Carolina Castro Ruiz verfasserin aut Antonio De Leo verfasserin aut Guido Giordano verfasserin aut Matteo Landriscina verfasserin aut Giuseppe Carrieri verfasserin aut Luigi Cormio verfasserin aut Daniel M. Berney verfasserin aut Jatin Gandhi verfasserin aut Giacomo Santandrea verfasserin aut Maria Carolina Gelli verfasserin aut Alessandro Tafuni verfasserin aut Moira Ragazzi verfasserin aut In Cells MDPI AG, 2012 10(2021), 11, p 3165 (DE-627)718622081 (DE-600)2661518-6 20734409 nnns volume:10 year:2021 number:11, p 3165 https://doi.org/10.3390/cells10113165 kostenfrei https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f kostenfrei https://www.mdpi.com/2073-4409/10/11/3165 kostenfrei https://doaj.org/toc/2073-4409 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 11, p 3165
allfieldsSound	10.3390/cells10113165 doi (DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f DE-627 ger DE-627 rakwb eng QH573-671 Andrea Palicelli verfasserin aut What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized. PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology Martina Bonacini verfasserin aut Stefania Croci verfasserin aut Cristina Magi-Galluzzi verfasserin aut Sofia Cañete-Portillo verfasserin aut Alcides Chaux verfasserin aut Alessandra Bisagni verfasserin aut Eleonora Zanetti verfasserin aut Dario De Biase verfasserin aut Beatrice Melli verfasserin aut Francesca Sanguedolce verfasserin aut Magda Zanelli verfasserin aut Maria Paola Bonasoni verfasserin aut Loredana De Marco verfasserin aut Alessandra Soriano verfasserin aut Stefano Ascani verfasserin aut Maurizio Zizzo verfasserin aut Carolina Castro Ruiz verfasserin aut Antonio De Leo verfasserin aut Guido Giordano verfasserin aut Matteo Landriscina verfasserin aut Giuseppe Carrieri verfasserin aut Luigi Cormio verfasserin aut Daniel M. Berney verfasserin aut Jatin Gandhi verfasserin aut Giacomo Santandrea verfasserin aut Maria Carolina Gelli verfasserin aut Alessandro Tafuni verfasserin aut Moira Ragazzi verfasserin aut In Cells MDPI AG, 2012 10(2021), 11, p 3165 (DE-627)718622081 (DE-600)2661518-6 20734409 nnns volume:10 year:2021 number:11, p 3165 https://doi.org/10.3390/cells10113165 kostenfrei https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f kostenfrei https://www.mdpi.com/2073-4409/10/11/3165 kostenfrei https://doaj.org/toc/2073-4409 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2021 11, p 3165
language	English
source	In Cells 10(2021), 11, p 3165 volume:10 year:2021 number:11, p 3165
sourceStr	In Cells 10(2021), 11, p 3165 volume:10 year:2021 number:11, p 3165
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy Cytology
isfreeaccess_bool	true
container_title	Cells
authorswithroles_txt_mv	Andrea Palicelli @@aut@@ Martina Bonacini @@aut@@ Stefania Croci @@aut@@ Cristina Magi-Galluzzi @@aut@@ Sofia Cañete-Portillo @@aut@@ Alcides Chaux @@aut@@ Alessandra Bisagni @@aut@@ Eleonora Zanetti @@aut@@ Dario De Biase @@aut@@ Beatrice Melli @@aut@@ Francesca Sanguedolce @@aut@@ Magda Zanelli @@aut@@ Maria Paola Bonasoni @@aut@@ Loredana De Marco @@aut@@ Alessandra Soriano @@aut@@ Stefano Ascani @@aut@@ Maurizio Zizzo @@aut@@ Carolina Castro Ruiz @@aut@@ Antonio De Leo @@aut@@ Guido Giordano @@aut@@ Matteo Landriscina @@aut@@ Giuseppe Carrieri @@aut@@ Luigi Cormio @@aut@@ Daniel M. Berney @@aut@@ Jatin Gandhi @@aut@@ Giacomo Santandrea @@aut@@ Maria Carolina Gelli @@aut@@ Alessandro Tafuni @@aut@@ Moira Ragazzi @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	718622081
id	DOAJ073495417
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073495417</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412132651.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cells10113165</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073495417</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH573-671</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Andrea Palicelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PD-L1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adenocarcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">target-therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Cytology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martina Bonacini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Croci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Magi-Galluzzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sofia Cañete-Portillo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alcides Chaux</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Bisagni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleonora Zanetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dario De Biase</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beatrice Melli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sanguedolce</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magda Zanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Paola Bonasoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Loredana De Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Soriano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Ascani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Zizzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carolina Castro Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio De Leo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Giordano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matteo Landriscina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Carrieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Cormio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel M. Berney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jatin Gandhi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giacomo Santandrea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Carolina Gelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Tafuni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moira Ragazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cells</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">10(2021), 11, p 3165</subfield><subfield code="w">(DE-627)718622081</subfield><subfield code="w">(DE-600)2661518-6</subfield><subfield code="x">20734409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:11, p 3165</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cells10113165</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2073-4409/10/11/3165</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2073-4409</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2021</subfield><subfield code="e">11, p 3165</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Andrea Palicelli
spellingShingle	Andrea Palicelli misc QH573-671 misc PD-L1 misc prostate misc cancer misc adenocarcinoma misc immunohistochemistry misc target-therapy misc Cytology What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
authorStr	Andrea Palicelli
ppnlink_with_tag_str_mv	@@773@@(DE-627)718622081
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QH573-671
illustrated	Not Illustrated
issn	20734409
topic_title	QH573-671 What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations PD-L1 prostate cancer adenocarcinoma immunohistochemistry target-therapy
topic	misc QH573-671 misc PD-L1 misc prostate misc cancer misc adenocarcinoma misc immunohistochemistry misc target-therapy misc Cytology
topic_unstemmed	misc QH573-671 misc PD-L1 misc prostate misc cancer misc adenocarcinoma misc immunohistochemistry misc target-therapy misc Cytology
topic_browse	misc QH573-671 misc PD-L1 misc prostate misc cancer misc adenocarcinoma misc immunohistochemistry misc target-therapy misc Cytology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cells
hierarchy_parent_id	718622081
hierarchy_top_title	Cells
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)718622081 (DE-600)2661518-6
title	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
ctrlnum	(DE-627)DOAJ073495417 (DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f
title_full	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
author_sort	Andrea Palicelli
journal	Cells
journalStr	Cells
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi
container_volume	10
class	QH573-671
format_se	Elektronische Aufsätze
author-letter	Andrea Palicelli
doi_str_mv	10.3390/cells10113165
author2-role	verfasserin
title_sort	what do we have to know about pd-l1 expression in prostate cancer? a systematic literature review. part 2: clinic–pathologic correlations
callnumber	QH573-671
title_auth	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
abstract	Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
abstractGer	Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
abstract_unstemmed	Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	11, p 3165
title_short	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations
url	https://doi.org/10.3390/cells10113165 https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f https://www.mdpi.com/2073-4409/10/11/3165 https://doaj.org/toc/2073-4409
remote_bool	true
author2	Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi
author2Str	Martina Bonacini Stefania Croci Cristina Magi-Galluzzi Sofia Cañete-Portillo Alcides Chaux Alessandra Bisagni Eleonora Zanetti Dario De Biase Beatrice Melli Francesca Sanguedolce Magda Zanelli Maria Paola Bonasoni Loredana De Marco Alessandra Soriano Stefano Ascani Maurizio Zizzo Carolina Castro Ruiz Antonio De Leo Guido Giordano Matteo Landriscina Giuseppe Carrieri Luigi Cormio Daniel M. Berney Jatin Gandhi Giacomo Santandrea Maria Carolina Gelli Alessandro Tafuni Moira Ragazzi
ppnlink	718622081
callnumber-subject	QH - Natural History and Biology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cells10113165
callnumber-a	QH573-671
up_date	2024-07-03T18:00:03.992Z
_version_	1803581762038661120
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ073495417</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412132651.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cells10113165</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ073495417</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ49bdba14c7fc4b88b941d1f188ef305f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QH573-671</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Andrea Palicelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic–pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PD-L1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adenocarcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">target-therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Cytology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martina Bonacini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Croci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Magi-Galluzzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sofia Cañete-Portillo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alcides Chaux</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Bisagni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eleonora Zanetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dario De Biase</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beatrice Melli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francesca Sanguedolce</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Magda Zanelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Paola Bonasoni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Loredana De Marco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Soriano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Ascani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Zizzo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carolina Castro Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio De Leo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guido Giordano</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matteo Landriscina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Carrieri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luigi Cormio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel M. Berney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jatin Gandhi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giacomo Santandrea</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Carolina Gelli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandro Tafuni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Moira Ragazzi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cells</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">10(2021), 11, p 3165</subfield><subfield code="w">(DE-627)718622081</subfield><subfield code="w">(DE-600)2661518-6</subfield><subfield code="x">20734409</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:11, p 3165</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cells10113165</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2073-4409/10/11/3165</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2073-4409</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2021</subfield><subfield code="e">11, p 3165</subfield></datafield></record></collection>
score	7.4024153

Nicht das Richtige dabei?

Schreiben Sie uns!

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?